Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

Share Price Information for CATCo (CAT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.00
Bid: 13.00
Ask: 35.00
Change: 0.00 (0.00%)
Spread: 22.00 (169.231%)
Open: 24.00
High: 24.00
Low: 24.00
Prev. Close: 24.00
CAT Live PriceLast checked at -
CATCo Reinsurance Opportunities is an Investment Trust

To provide investors with significant capital returns and long-term distributions by making investments linked to catastrophe reinsurance risks via a variety of insurance-based investments.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transaction in Own Shares - Compulsory Redemption

12 Jan 2021 07:00

RNS Number : 3235L
CATCo Reinsurance Opps Fund Ltd
12 January 2021
 

CATCo Reinsurance Opportunities Fund Limited (the "Company")

12 January 2021

Partial Compulsory Redemption of Shares

Following the redemption of 7,541,412 Ordinary Shares at a rate of $0.2652 per Ordinary Share and 11,808,631 C Shares at a rate of $0.5081 per C Share on 11 January 2021 (as previously announced on 13 March 2020 and updated on 23 December 2020), the Company now has 161,357,581 Ordinary Shares in issue and 114,560,954 C Shares in issue. With effect from today, the Company's Ordinary Shares will trade under the new ISIN number BMG1961Q2749 and the C Shares will trade under the new ISIN number BMG1961Q2822.

The applicable redemption ratios were 0.044650816 in relation to the Ordinary Shares and 0.093445736 in relation to the C Shares. On this basis, a holder of 100,000 Ordinary Shares will have had 4,465 Ordinary Shares redeemed, and receive $1,184.11 in cash. A holder of 100,000 C Shares will have had 9,344 C Shares redeemed, and receive $4,747.68 in cash. Approximately 6.55% of the issued share capital was redeemed.

In conformity with the FCA's Disclosure Guidance and Transparency Rules (DTR 5.6.1), the Company notifies that the Company's issued share capital now consists of 161,357,581 Ordinary Shares and 114,560,954 C Shares. Accordingly, the total number of voting rights in the Company is 275,918,535.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules (DTR 5.1.2).

It is expected that the proceeds of the redemption will be paid through CREST to holders of Ordinary Shares and C Shares in uncertificated form on 15 January 2021, and paid by cheque to holders of Ordinary Shares in certificated form on 21 January 2021.

Capitalised terms used but not defined in this announcement shall bear the meanings ascribed to them in the Circular to Shareholders dated 13 March 2020.

 Enquiries:

For further information:

Markel CATCo Investment Management Ltd.

 

Judith Wynne

General Counsel

Telephone: +1 441 493 9005

Email: judith.wynne@markelcatco.com

 

Mark Way

Chief of Investor Marketing

Telephone: +1 441 493 9001

Email: mark.way@markelcatco.com

 

Numis Securities Limited

 

David Benda / Hugh Jonathan

Telephone: +44 (0) 20 7260 1000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSEADFFFDLFEAA
Date   Source Headline
30th Jun 20064:12 pmRNSHolding(s) in Company
30th Jun 20064:06 pmRNSDelisting
30th Jun 200610:27 amRNSAdditional Listing
30th Jun 20067:02 amRNSOffer for Cambridge Antibody
27th Jun 20062:26 pmRNSHolding(s) in Company
27th Jun 200612:34 pmRNSHolding(s) in Company
23rd Jun 20062:25 pmRNSAppointment of Directors
22nd Jun 20063:07 pmRNSRule 8.3- CAT
22nd Jun 200611:31 amRNSCAT Limited appoints new CE
22nd Jun 200611:11 amRNSEPT Disclosure
22nd Jun 200611:09 amRNSEPT Disclosure
22nd Jun 20067:02 amRNSOffer for Cambridge Antibody
21st Jun 20065:11 pmRNSRule 8.1- C.A.T.
21st Jun 200611:30 amRNSEPT Disclosure
21st Jun 200610:20 amRNSEPT Disclosure
20th Jun 200610:36 amRNSEPT Disclosure
20th Jun 200610:36 amRNSEPT Disclosure
19th Jun 20063:25 pmRNSRule 8.3 - Cambridge Antibody
19th Jun 20061:07 pmRNSRule 8.3- (CAT)
19th Jun 200611:30 amRNSEPT Disclosure
19th Jun 200611:23 amRNSEPT Disclosure
19th Jun 200610:33 amRNSEPT Disclosure
16th Jun 200611:45 amRNSEPT Disclosure
16th Jun 200611:24 amRNSEPT Disclosure
16th Jun 200611:08 amRNSEPT Disclosure
15th Jun 20065:01 pmRNSEPT Disclosure
15th Jun 20062:48 pmRNSRule 8.3- (CAT)
15th Jun 20062:17 pmRNSRule 2.10 Announcement
15th Jun 200612:45 pmRNSEPT Disclosure
15th Jun 200611:36 amRNSEPT Disclosure
14th Jun 20063:38 pmRNSRule 8.3- Cambridge Antibody
14th Jun 20063:05 pmRNSRule 8.3- Cambridge Antibody
14th Jun 20061:43 pmRNSRule 8.3- (CAT)
14th Jun 200611:36 amRNSEPT Disclosure
14th Jun 200611:15 amRNSEPT Disclosure
14th Jun 200610:59 amRNSEPT Disclosure
14th Jun 200610:23 amRNSEPT Disclosure
13th Jun 20064:50 pmRNSRule 8.3- Cambridge Antibody
13th Jun 20063:54 pmRNSRule 2.10 Announcement
13th Jun 200612:18 pmRNSEPT Disclosure
13th Jun 200611:42 amRNSEPT Disclosure
13th Jun 200611:35 amRNSEPT Disclosure
13th Jun 200610:20 amRNSEPT Disclosure
12th Jun 20065:35 pmRNSRule 8.3 - Cambridge Antibody
12th Jun 200612:00 pmRNSEPT Disclosure
12th Jun 200611:34 amRNSEPT Disclosure
12th Jun 200611:14 amRNSRule 8.3- (CAT)
12th Jun 200610:08 amRNSEPT Disclosure
12th Jun 20067:00 amRNSRule 8.3- Cambridge Antibody
9th Jun 20061:30 pmRNSRule 8.3- (CAT)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.